• Niclosamide Workflows for STAT3 Cancer Research

  2026-10-01

  Build stronger cancer research workflows with Niclosamide by pairing STAT3 Tyr-705 measurements with viability, apoptosis, and cell-cycle endpoints. This practical guide adapts concentration–time design principles from a comparative biological study without overstating cross-domain evidence.

• WP1066: JAK2/STAT3 Inhibitor Evidence Guide

  2026-10-01

  WP1066 is a cell-permeable JAK2/STAT3 inhibitor that suppresses JAK2 phosphorylation and downstream STAT3, STAT5, and PI3K signaling in experimental cancer models. Product information reports activity in Caki-1 renal carcinoma xenografts and AML models, while an independent ACS Nano study provides pathway context for JAK2-STAT3 signaling in reparative macrophages.

• RepSox and the Next Era of hiPSC Platelet Research

  2026-09-30

  RepSox offers a mechanistically precise way to interrogate ALK5-dependent TGF-β signaling during stem cell engineering. Paired with recent advances in hiPSC-derived platelet production, it supports a strategic path from empirical protocol optimization toward pathway-informed, reproducible translational workflows.

• IDO1 Blockade Activates Tumor-Protective JAK2/STAT3

  2026-09-29

  The 2024 Journal of Immunology study shows that pharmacological apo-IDO1 inhibition can activate antitumor immune populations while simultaneously inducing an IL-6–JAK2–STAT3 survival program inside tumor cells. Its single-cell analysis explains how this compensatory response may limit the benefit of IDO1 blockade and supports testing pathway-directed combination strategies.

• CD40–STING–TRAF2 Axis in ESCC TLS

  2026-09-29

  This study identifies tertiary lymphoid structures as favorable prognostic features in treatment-naïve esophageal squamous cell carcinoma and defines a CD40–STING–TRAF2 mechanism controlling IRF4-positive B-cell activation. Its integrated tissue, transcriptomic, single-cell, and in vitro analyses provide a framework for interpreting TLS-associated antitumor immunity and developing mechanistically informed biomarkers.

• Cyclic Pifithrin-α hydrobromide Workflow

  2026-09-28

  Build a controlled p53 perturbation workflow for DNA-damage, apoptosis, and growth-arrest studies with Cyclic Pifithrin-α hydrobromide. The same design can be adapted as an exploratory overlay on calcium-driven neuroinflammation while preserving the distinction between established evidence and testable hypotheses.

• Low-Dose Cadmium Activates STAT3 in Lymphangiogenesis

  2026-09-28

  The reference study identifies STAT3 as a central mediator of cadmium-enhanced lymphangiogenesis after corneal injury. Using mouse exposure models and human dermal lymphatic endothelial cells, the authors connect cadmium-dependent STAT3 phosphorylation to VEGFR3 regulation, endothelial proliferation, and migration, while pharmacologic STAT3 inhibition suppresses these responses.

• DAPI Nuclear Stain Solution: Practical Workflow

  2026-09-27

  DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a ready-to-use fluorescent DNA stain for visualizing nuclei and assessing membrane-compromised cells. It is suited to fixed or permeable samples and endpoint microscopy or flow cytometry, but limited cell permeability makes it unsuitable as a general stain for intact live-cell imaging.

• I-BET151 and the SLC7A11 Super-Enhancer Axis

  2026-09-26

  Explore how I-BET151 (GSK1210151A) could help test the connection between BET-dependent transcription and the FOXA1–SLC7A11 axis in prostate cancer. This evidence-led guide separates findings established in the literature from hypotheses that require direct validation.

• Cediranib (AZD2171): Better In Vitro Readouts

  2026-09-25

  A practical guide to using Cediranib (AZD2171), SKU A1882, to investigate VEGFR signaling and interpret cell-response assays without equating pathway inhibition with cell killing. It combines product-backed potency and handling details with experimental design guidance and clear limits on what in vitro results establish.

• Nintedanib (BIBF 1120) in ATRX-Glioma Research

  2026-09-25

  Use Nintedanib (BIBF 1120) to probe VEGFR, FGFR, and PDGFR signaling in angiogenesis and tumor-cell assays, with a workflow designed to test—not assume—ATRX-linked sensitivity. Practical dosing, vehicle controls, and assay readouts help distinguish target engagement from nonspecific toxicity.

• AZD1480: JAK2 Inhibition in Tumor Models

  2026-09-24

  AZD1480 is a potent JAK2 inhibitor reported to suppress JAK2-mediated STAT3 signaling and cancer-cell growth in preclinical models. Its mechanism provides a research rationale for testing tumor-intrinsic JAK2/STAT3 activation, including the IL-6-linked response reported after IDO1 inhibition, but does not establish clinical efficacy or a validated combination regimen.

• Cediranib (AZD2171): Reading Drug Response in Time

  2026-09-24

  Cediranib (AZD2171) can suppress VEGFR signaling without producing an immediate loss of cell viability. This guide applies a key insight from cancer-response measurement research—separating growth inhibition from cell killing—to help researchers interpret Cediranib experiments over time.

• AZD1480: A JAK2/STAT3 Research Inhibitor

  2026-09-23

  AZD1480 is an ATP-competitive JAK2 inhibitor with a reported 0.26 nM IC50 in the product assay. It suppresses JAK2-dependent STAT3 signaling and provides a research tool for studying myeloma, solid-tumor, angiogenesis, metastasis, and cytokine-driven resistance mechanisms.

• Imatinib Hydrochloride: State-Aware Assays

  2026-09-22

  Imatinib hydrochloride is more than an ATP-site probe: its assay interpretation depends on target selectivity, kinase conformation, and phosphatase-driven signal decay. This guide connects STI571 hydrochloride research with structural insights from p38α kinase biology while defining practical controls for CML and GIST studies.

541 records 2/37 page Previous Next 12345 下5页 Last page